Roche
NEWS
Novo Nordisk and Dicerna are no strangers. The companies have been collaborating on the development of RNAi therapies for liver disease for the past three years.
AC Immune’s Phase II Lauriet study of investigational anti-Tau monoclonal antibody, semorinemab, in mild-to-moderate Alzheimer’s disease (AD), only met one endpoint.
Alltrna, based in Cambridge, Mass. near its cousin Moderna, debuts as the first platform transfer RNA (tRNA) company.
Bristol Myers Squibb’s Phase III CheckMate -816 trial hit the primary endpoint in an interim analysis.
For the past 20 years, Novartis has held a 33% stake in Roche, its Basel, Switzerland neighbor. Now, Novartis has divested its one-third stake to Roche for a whopping $20.7 billion.
GlaxoSmithKline denied reports that they were interested in acquiring Canada’s Aurinia Pharmaceuticals, although some reports claim they are preparing to bid.
AT-527, an oral direct-acting antiviral agent that blocks viral RNA polymerase needed for viral replication, failed to meet its primary endpoint in the Phase II MOONSONG study.
The FDA reviewed Tecentriq under Project Orbis, allowing the simultaneous submission and review of potential oncology treatments to international regulatory bodies.
Takeda entered into a licensing pact with Poseida, Spark entered into a licensing agreement with CombiGene AB, while BridgeBio Pharma announced plans for its second annual R&D Day.
JOBS
IN THE PRESS